Price
244.55
+0.32%52W Range
Market Cap
₹331.68 Cr
Traded: ₹0.81 Cr (0.24%) 0.0x
Free Float: ₹124.15 Cr (0.65% of FF traded)
Volume · 60D trend
32.78 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +6.0% | +4.0% | -- | -- | Decelerating |
| Sales | -- | +12.0% | +12.0% | -- | +25.0% | Stable |
| Profit | -- | -4.0% | -13.0% | -- | +14.0% | Stable |
| Return | +3.0% | -20.0% | -32.0% | -32.0% | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48 | 61 | 47 | 47 | 43 | 30 | 45 | 45 | 43 | 47 | 47 | 44 | 42 | 39 | 36 | 34 |
| Expenses | 44 | 55 | 43 | 42 | 38 | 31 | 38 | 39 | 40 | 42 | 42 | 39 | 35 | 32 | 30 | 28 |
| Operating Profit | 4 | 5 | 4 | 5 | 5 | -2 | 7 | 5 | 3 | 6 | 5 | 5 | 7 | 6 | 6 | 6 |
| OPM % | 9.0% | 8.9% | 9.3% | 10.9% | 10.7% | -5.4% | 14.9% | 11.9% | 8.0% | 12.2% | 10.5% | 10.7% | 16.6% | 16.8% | 16.5% | 17.5% |
| Other Income | 1 | 2 | 1 | 0 | 0 | 5 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit Before Tax | 3 | 5 | 2 | 3 | 2 | 2 | 4 | 2 | 2 | 3 | 3 | 2 | 5 | 4 | 4 | 4 |
| Tax % | 28.4% | 12.1% | 22.3% | 21.3% | 24.9% | 25.3% | 24.7% | 53.9% | 48.7% | 22.9% | 38.1% | 39.7% | 15.8% | 13.5% | 10.7% | 13.0% |
| Net Profit | 2 | 4 | 2 | 2 | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 1 | 4 | 4 | 4 | 4 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 1.6 | 2.9 | 1.6 | 2.0 | 1.6 | 1.9 | 2.7 | 1.1 | 1.1 | 1.7 | 1.9 | 1.2 | 3.3 | 3.1 | 3.0 | 2.9 |
| Sales Growth (YoY) | 11.3% | 104.8% | 3.9% | 5.4% | -0.0% | -37.4% | -2.9% | 2.8% | 2.6% | 22.4% | 30.7% | 29.9% | 26.8% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 29.3% | -0.6% | 9.6% | 45.4% | -34.4% | 0.9% | 3.9% | -9.0% | 1.8% | 6.8% | 3.8% | 8.5% | 8.7% | 6.1% | -- |
| OP Growth (YoY) | -6.1% | 437.3% | -34.7% | -2.8% | 33.6% | -128.0% | 36.9% | 14.2% | -50.4% | -11.4% | -16.5% | -20.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | -20.3% | 24.0% | -15.1% | 11.9% | 386.3% | -124.0% | 26.4% | 53.9% | -40.0% | 17.3% | 5.4% | -33.1% | 7.1% | 10.6% | 0.2% | -- |
| Profit Growth (YoY) | -1.4% | 59.5% | -36.9% | 82.9% | 59.3% | 13.6% | 44.6% | -3.3% | -67.7% | -45.2% | -36.2% | -58.1% | 16.4% | 41.5% | -0.5% | -15.0% |
| EPS Growth (YoY) | -- | 50.0% | -41.0% | 71.3% | 50.0% | 13.1% | 43.7% | -3.4% | -67.9% | -45.3% | -36.0% | -58.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 77.0% | -18.3% | 23.9% | -16.3% | -30.4% | 137.4% | 8.5% | -36.9% | -11.6% | 59.7% | -63.9% | 7.5% | 3.4% | 4.2% | -- |
| OP Margin | -- | 8.9% | 9.3% | 10.9% | 10.7% | -5.4% | 14.9% | 11.9% | 8.0% | 12.2% | 10.5% | 10.7% | 16.6% | 16.8% | 16.5% | 17.5% |
| Net Margin | -- | 7.3% | 3.5% | 4.5% | 3.7% | 6.3% | 6.5% | 2.0% | 1.9% | 4.3% | 4.4% | 3.4% | 9.4% | 9.8% | 10.6% | 10.7% |
| Material Cost % | 44.1% | 53.1% | 50.5% | 49.1% | 52.8% | 46.5% | 49.5% | 54.6% | 56.0% | 49.9% | 53.7% | 53.2% | 49.8% | 56.0% | 48.0% | 49.4% |
| Employee Cost % | 19.4% | 15.5% | 17.8% | 18.7% | 18.8% | 28.4% | 17.7% | 17.1% | 18.2% | 17.7% | 17.2% | 16.3% | 15.6% | 14.0% | 16.0% | 14.6% |
| P/S | 1.63 | 1.65 | 2.32 | 2.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 30.61 | 29.98 | 40.31 | 36.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.20 | 1.18 | 1.40 | 1.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Company has fixed Saturday, September 19, 2026 as the record date for determining the entitlement of members to receive the dividend, if declared at the ensuing AGM.
Corporate Action- Fixes Record Date as September 19, 2026 for the purpose of declaration of final dividend for FY 2025-26.
Announcement under Regulation 30 (LODR)- Newspaper Publication for the Unaudited Standalone and Consolidated Financial Results for the Qtr ended 30.06.2026
Board of Directors has been approved the closure of Register of Members and Share Transfer Books from September 19, 2026 to September 25, 2026 in connection with the proposed payment of ....
Financial Results for the quarter ended on June 30, 2026.
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation for closure of trading window
Announcement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026
Statement of Deviation & Variation Report - March 31, 2026
The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each ....
Audited Standalone & Consolidated Financial Results for the quarter and year ended on March 31, 2026
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the audited financial results ....
Compliance Certifcate under Reg 74 (5) of SEBI (DP) Regulation , 2018
Intimation regarding Incorrent Event Display on NSDL Portal
Intimation of Closure of Trading Window - March 2026
The company has on 27.01.2026 received a cautionery letter (Email) from NSE for observations reported by the Secretarial Auditor in ASCR for FY ended 31.03.2025.
Corrigendum- Intimation regarding completion of term of Independent Directorship of Mr Harish Pande and Mr Arun Kumar
Announcement under Regulation 30 (LODR) - Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligatons and Disclosure Requirements) Regulations 2025, the Company hereby informs that Mr. Harish Pande and Mr. Arun Kumar have completed ....
Unaudited Financial Results for the quarter ended on December 31, 2025
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the unaudited consolidated ....
Compliance- Certificate under Reg 74 (5) of SEBI (DP) Regulations 2018
Announcement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark
Closure of Trading Window - For declaration of unaudited financial results for the quarter ended on December 31, 2025
Announcement under Regulation 30 (LODR) - Newspaper Publication
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve unaudited Financial Results ....
Compliance - Certificate under Regulation 74 (5) of SEBI (DP) Regulation, 2018
Intimation of Clsoure of Trading Window
Voting Results of the 32nd AGM along with the consolidated Scrutinizer Report.
Outcome of the 32nd Annual General Meeting of the Company.
Please find enclosed herewith the revised intimation for Book Closure for the purpose of 32nd Annual general Meeting of the Company.
Please find enclosed herewith the intimation for Book Closure for the purpose of the 32nd Annual General Meeting of the Company.
Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find ....
Announcement under Regulation 30 (LODR) - Change in management
Business Responsibility and Sustainability Report - 2024-25
Outcome of the Board meeting held on August 12, 2025
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve unaudited (Standalone and ....
Compliance - Certificate under Reg 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading window
Announcement under Regulation 30 (LODR) - Approval of Abbreviated New Drug Application (ANDA)
Newspaper publication of Audited Financial Results for the quarter and year ended on March 31, 2025
Compliance - Reg 24 (A)- Annual Secretarial Compliance Report - March 31, 2025
Financial Results year ended on 31.03.2025
Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve Medicamen Biotech Limited ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shivalik Rasayan Ltd & PACs
Corrigendum to the Outcome of the meeting of the Board Meeting of Board of Directors of Medicamen Biotech Limited ("the Company") in accordance with Regulation 30 of the Securities and ....
Revised outcome of Board Meeting - 24.04.2025
Outcome of Board Meeting - April 24, 2025
We wish to inform you that the Board of Directors of the Company at their meeting held today i.e Thursday, April 24, 2025 has inter alia considered and approved the following : 1. Allotment ....
Certificate under Regulation 75 (5) of SEBI (DP) Regulations, 2018
Annual Reports
15Credit Ratings
6